利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.026 秒)

    Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
    1.
    发明申请
    Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens 审中-公开
    通过柔性接头稳定的HIF-1包膜糖蛋白作为有效的入侵抑制剂和免疫原

    公开(公告)号：US20050106160A1

    公开(公告)日：2005-05-19

    申请号：US10506651

    申请日：2002-03-05

    申请人： Dimiter Dimitrov ,  Yen-Hung Chow ,  Sanjay Phogat ,  Christopher Broder

    发明人： Dimiter Dimitrov ,  Yen-Hung Chow ,  Sanjay Phogat ,  Christopher Broder

    IPC分类号： A61K39/21 ,  C07H21/04 ,  C07K14/16

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/545 ,  C07H21/04 ,  C12N2740/16122 ,  C12N2740/16134

    摘要： This invention relates generally to immune responses to human immunodeficiency virus coat protein gp160 presented in the form of antigenic compositions, nucleic acids encoding human immunodeficiency virus coat proteins, and vaccines. The invention also relates to methods for production of antigenic compositions containing human immunodeficiency virus coat protein, nucleic acids encoding human immunodeficiency virus coat proteins, and human immunodeficiency virus vaccines. The invention comprises gp120 and gp41 subunits of the human immunodeficiency virus coat protein covalently linked through a peptide linker, as well as additional complexes including those comprising the human immunodeficiency virus coat protein and it's natural cellular receptor molecules.

    摘要翻译： 本发明一般涉及抗原组合物形式的人免疫缺陷病毒外壳蛋白gp160的免疫应答，编码人免疫缺陷病毒外壳蛋白的核酸和疫苗。 本发明还涉及含有人免疫缺陷病毒外壳蛋白，编码人免疫缺陷病毒外壳蛋白的核酸和人免疫缺陷病毒疫苗的抗原组合物的制备方法。 本发明包括通过肽接头共价连接的人免疫缺陷病毒外壳蛋白的gp120和gp41亚基，以及包括人免疫缺陷病毒外壳蛋白和其天然细胞受体分子的其它复合物。

    BROADLY CROSS-REACTIVE NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS SELECTED BY ENV-CD4-CO-RECEPTOR COMPLEXES
    2.
    发明申请
    BROADLY CROSS-REACTIVE NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS SELECTED BY ENV-CD4-CO-RECEPTOR COMPLEXES 失效
    通过ENV-CD4-CO受体复合物选择的人类免疫缺陷病毒的广泛的交叉反应性中和抗体

    公开(公告)号：US20070212349A1

    公开(公告)日：2007-09-13

    申请号：US11748992

    申请日：2007-05-15

    申请人： Dimiter Dimitrov ,  Maxime Moulard ,  Xiadong Xiao ,  Yuuei Shu ,  Sanjay Phogat ,  Mei-Yun Zhang ,  Dennis Burton

    发明人： Dimiter Dimitrov ,  Maxime Moulard ,  Xiadong Xiao ,  Yuuei Shu ,  Sanjay Phogat ,  Mei-Yun Zhang ,  Dennis Burton

    IPC分类号： A61K39/395 ,  C12N5/06 ,  C12N5/16

    CPC分类号： C07K16/1063 ,  A61K2039/505 ,  C07K14/70514 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2319/00

    摘要： The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.

    摘要翻译： 本发明的特征在于特异性结合CD4诱导型HIV gp120表位的抗体和抗体片段，其通过结合HIV的共受体（例如CCR5或CXCR4）而增强，以及包含抗体或抗体片段的药物组合物。 本发明还具有编码抗体或抗体片段的核酸，包含编码抗体或抗体片段的核酸，包含核酸的载体和包含载体的细胞的药物组合物。 本发明进一步具有鉴定具有对HIV广泛中和活性的抗体或抗体片段的方法。 本发明还涉及使用本发明的抗体和核酸来抑制HIV进入细胞的方法和抑制哺乳动物HIV复制的方法。

    IMMUNOGEN PRIORITIZATION FOR VACCINE DESIGN
    4.
    发明申请
    IMMUNOGEN PRIORITIZATION FOR VACCINE DESIGN 审中-公开
    疫苗免疫优化设计

    公开(公告)号：US20110123556A1

    公开(公告)日：2011-05-26

    申请号：US12951675

    申请日：2010-11-22

    申请人： Sanjay Phogat ,  Christopher Marshall

    发明人： Sanjay Phogat ,  Christopher Marshall

    IPC分类号： G01N33/53 ,  A61K39/00 ,  A61P37/04 ,  A61P31/00 ,  A61P31/04 ,  A61P33/02 ,  A61P31/12 ,  A61P31/18 ,  B82Y15/00

    CPC分类号： G01N33/56972 ,  B82Y15/00

    摘要： The present invention provides a method of prioritizing vaccine immunogens, using human iNKT-cell and B-cells, that enables screening of large numbers of immunogens simultaneously in-vitro for diseases and any other vaccine related application, that may then be further tested and improved upon in iterative application of the present technology and other methods of analyzing immunogens. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

    摘要翻译： 本发明提供了使用人类iNKT细胞和B细胞优先使用疫苗免疫原的方法，其能够在体外同时筛选大量的免疫原，用于疾病和任何其它疫苗相关应用，然后可以进一步测试和改进 在本技术的迭代应用和其他分析免疫原的方法中。 本发明包括配制成本发明疫苗的免疫原性组合物的制备和纯化。